Therapeutics of Vein Graft Intimal Hyperplasia: 100 Years On

Annals of Thoracic Surgery

Volumn 84, Issue 1, 2007, Pages 317-323

  Wallitt, Edward J W ^a   Jevon, Marc ^a   Hornick, Philip I ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL RESEARCH; CORONARY ARTERY BYPASS GRAFT; HUMAN; INFLAMMATION; INTIMA; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK FACTOR; STEM CELL; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VEIN GRAFT;

ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; CELL PROLIFERATION; CORONARY ARTERY BYPASS; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; PLATELET AGGREGATION INHIBITORS; SAPHENOUS VEIN; SHEAR STRENGTH; SIROLIMUS; STRESS, MECHANICAL; TUNICA INTIMA; VASCULAR PATENCY; VEINS;

EID: 34250333310     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.02.035     Document Type: Review

References (83)

1. Carrel A.G.C. Uniterminal and biterminal venous transplantations. Surg Gynecol Obstet (1906) 266-286
2. Grondin C.M., Meere C., Castonguay Y., Lepage G., and Grondin P. Progressive and late obstruction of an aorto-coronary venous bypass graft. Circulation 43 (1971) 698-702
3. Smith S.H., and Geer J.C. Morphology of saphenous vein-coronary artery bypass grafts: seven to 116 months after surgery. Arch Pathol Lab Med 107 (1983) 13-18
4. Goldman S., Zadina K., Moritz T., et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 44 (2004) 2149-2156
5. Kim D.W., Chung H.J., Nose K., Maruyma I., and Tani T. Preventative effects of traditional Chinese formulation, Chaihu-jia-Longgu-Muli-tang, on intimal thickening of carotid artery injured by balloon endothelial denudation in rate. J Pharm Pharmacol 54 (2002) 571-575
6. Slomp J., van Munsteren J.C., Poelmann R.E., de Reeder E.G., Bogers A.J., and Gittenberger-de Groot A.C. Formation of intimal cushions in the ductus arteriosus as a model for vascular intimal thickening: an immunohistochemical study of changes in extracellular matrix components. Atherosclerosis 93 (1992) 25-39
7. Zubilewicz T., Wronski J., and Bourriez A. Injury in vascular surgery-the intimal hyperplastic response. Med Sci Monit 7 (2001) 316-324
8. Anitschkow N., and Chalatow S. Ueber experimentelle cholesterinsteatose und ihre bedeutung fur die entstehung einiger pathologischer prozesse. Centrble Allg Pathol Anat 24 (1913) 1-9
9. Schwartz S.M., deBlois D., and O'Brien E.R. The intima: soil for atherosclerosis and restenosis. Circ Res 77 (1995) 445-465
10. Ratliff N.B., and Myles J.L. Rapidly progressive atherosclerosis in aortocoronary saphenous vein grafts: possible immune-mediated disease. Arch Pathol Lab Med 113 (1989) 772-776
11. Kalan J.M., and Roberts W.C. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am Heart J 119 (1990) 1164-1184
12. Tennant M., and McGeachie J.K. Adaptive remodelling of smooth muscle in the neo-intima of vein-to-artery grafts in rats: a detailed morphometric analysis. Anat Embryol (Berl) 187 (1993) 161-166
13. Lau G.T., Ridley L.J., and Bannon P.G. Lumen loss in the first year in saphenous vein grafts is predominantly a result of negative remodeling of the whole vessel rather than a result of changes in wall thickness. Circulation 114 (2006) 435-440
14. Allaire E., and Clowes A.W. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg 63 (1997) 582-591
15. Fingerle J., Au Y.P., Clowes A.W., and Reidy M.A. Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 10 (1990) 1082-1087
16. Raja S.G., Haider Z., Ahmad M., and Zaman H. Saphenous vein grafts: to use or not to use?. Heart Lung Circ 13 (2004) 403-409
17. van Beusekom H.M., Whelan D.M., Hofma S.H., et al. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol 32 (1998) 1109-1117
18. Xu Q. The impact of progenitor cells in atherosclerosis. Nat Clin Pract 3 (2006) 94-101
19. Kipshidze N., Dangas G., Tsapenko M., et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 44 (2004) 733-739
20. Brody W.R., Angeli W.W., and Kosek J.C. Histologic fate of the venous coronary artery bypass in dogs. Am J Pathol 66 (1972) 111-130
21. Angelini G.D., Passani S.L., Breckenridge I.M., and Newby A.C. Nature and pressure dependence of damage induced by distension of human saphenous vein coronary artery bypass grafts. Cardiovasc Res 21 (1987) 902-907
22. Leask R.L., Butany J., and Johnston K.W. Human saphenous vein coronary artery bypass graft morphology, geometry and haemodynamics. Ann Biomed Eng 33 (2005) 301-309
23. Sterpetti A.V., Cucina A., Lepidi S., et al. Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblastic growth factor production. J Vasc Surg 23 (1996) 568-575
24. Lemson M.S., Tordoir J.H., Daemen M.J., and Kitslaar P.J. Intimal hyperplasia in vascular grafts. Eur J Vasc Endovasc Surg 19 (2000) 336-350
25. Mitra A.K., Gangahar D.M., and Agrawal D.K. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft hyperplasia. Immunol Cell Biol 84 (2006) 115-124
26. Franklin L.R., He G.W., Buxton B.F., and Angus J.A. Pharmacology of coronary artery bypass grafts. Ann Thoracic Surg 67 (1999) 878-888
27. He G.W., Rosenfeldt F.L., and Angus J.A. Pharmacological relaxation of the saphenous vein during harvesting for coronary artery bypass grafting. Ann Thorac Surg 55 (1993) 1210-1217
28. Souza D.S.R., Johansson B., Bojo L., et al. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized longitudinal trial. J Thorac Cardiovasc Surg 132 (2006) 373-378
29. Mehta D., George S.J., Jeremy J.Y., et al. External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med 4 (1998) 235-239
30. Knatterud G.L., Rosenberg Y., Campeau L., et al., Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 102 (2000) 157-165
31. Wilentz J.R., Sanborn T.A., Haudenschild C.C., Valeri C.R., Ryan T.J., and Faxon D.P. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 75 (1987) 636-642
32. Ishiwata S., Tukada T., Nakanishi S., Nishiyama S., and Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133 (1997) 387-392
33. Yamaguchi M., Du W., Gould K.E., Dieffenbach C.W., Cruess D.F., and Sharefkin J.B. Effects of aspirin, dipyridamole, and dibutyryl cyclic adenosine monophosphate on platelet-derived growth factor A chain mRNA levels in human saphenous vein endothelial cells and smooth muscle cells. Surgery 110 (1991) 377-383 discussion 383-4
34. Landymore R.W., MacAulay M.A., and Manku M.S. The effects of low, medium and high dose aspirin on intimal proliferation in autologous vein grafts used for arterial reconstruction. Eur J Cardiothorac Surg 4 (1990) 441-444
35. Torsney E., Mayr U., Zou Y., Thompson W.D., Hu Y., and Xu Q. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. Circ Res 94 (2004) 1466-1473
36. Hermann A., Weber A.A., and Schror K. Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells. Thromb Res 105 (2002) 173-175
37. Kulik A., Le May M., Wells G.A., Mesana T.G., and Ruel M. The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med 6 (2005) 15
38. Wilson N.V., Salisbury J.R., and Kakkar V.V. The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg 8 (1994) 60-64
39. Lin P.H., Chen C., Bush R.L., Yao Q., Lumsden A.B., and Hanson S.R. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. J Vasc Surg 39 (2004) 1322-1328
40. Mureebe L., Turnquist S.E., and Silver D. Inhibition of intimal hyperplasia by direct thrombin inhibitors in an animal vein bypass model. Ann Vasc Surg 18 (2004) 147-150
41. Huynh T.T., Davies M.G., Thompson M.A., Ezekowitz M.D., Hagen P., and Annex B.H. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts. J Vasc Surg 33 (2001) 400-407
42. Oltrona L., Speidel C.M., Recchia D., Wickline S.A., Eisenberg P.R., and Abendschein D.R. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 96 (1997) 646-652
43. Hoch J.R., Stark V.K., van Rooijen N., Kim J.L., Nutt M.P., and Warner T.F. Macrophage depletion alters vein graft intimal hyperplasia. Surgery 126 (1999) 428-437
44. Mann M.J., Gibbons G.H., Tsao P.S., et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 99 (1997) 1295-1301
45. Perkins N.D., Felzien L.K., Betts J.C., Leung K., Beach D.H., and Nabel G.J. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275 (1997) 523-527
46. Wolff R.A., Ryomoto M., Stark V.E., et al. Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J Vasc Surg 41 (2005) 498-508
47. Nakao A., Otterbein L.E., Overhaus M., et al. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 127 (2004) 595-606
48. Hu X., Zhang Q., Sun D., Duan P., Wang X., and Duan Z. The gene expression of nuclear transcriptional factor-kappa B and I kappa B in autogenous vein graft in rats. Zhonghua Yi Xue Za Zhi 82 (2002) 1546-1549
49. Miyake T., Aoki M., Shiraya S., et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol 41 (2006) 431-440
50. Monaco C., and Paleolog E. Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61 (2004) 671-682
51. Newby A.C., and Zaltsman A.B. Molecular mechanisms in intimal hyperplasia. J Pathol 190 (2000) 300-309
52. Galis Z.S., Muszynski M., Sukhova G.K., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75 (1994) 181-189
53. Clowes A.W., Clowes M.M., Au Y.P., Reidy M.A., and Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 67 (1990) 61-67
54. Kenagy R.D., and Clowes A.W. Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors. Thromb Res 77 (1995) 55-61
55. Pintucci G., Saunders P.C., Gulkarov I., et al. Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts. Faseb J 20 (2006) 398-400
56. Ruef J., Meshel A.S., Hu Z., et al. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat. Circulation 100 (1999) 659-665
57. Petrofski J.A., Hata J.A., Williams M.L., et al. A Gbetagamma inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J Thorac Cardiovasc Surg 130 (2005) 1683-1690
58. Sun S., Beitler J.J., Ohki T., et al. Inhibitory effect of brachytherapy on intimal hyperplasia in arteriovenous fistula. J Surg Res 115 (2003) 200-208
59. Davies M.G., Klyachkin M.L., Barber L., Svendsen E., and Hagen P.O. Ramipril and experimental vein graft intimal hyperplasia. Angiology 46 (1995) 91-97
60. Huang P., Hawthorne W.J., Peng A., Angeli G.L., Medbury H.J., and Fletcher J.P. Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. Am J Surg 181 (2001) 492-498
61. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., and Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1345 (1997) 259-268
62. Harris M.B., Blackstone M.A., Sood S.G., et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287 (2004) H560-H566
63. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
64. Yamanouchi D., Banno H., Nakayama M., et al. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg 42 (2005) 757-764
65. Corpataux J.M., Naik J., Porter K.E., and London N.J. A comparison of six statins on the development of intimal hyperplasia in a human vein culture model. Eur J Vasc Endovasc Surg 29 (2005) 177-181
66. Dzau V.J., Braun-Dullaeus R.C., and Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8 (2002) 1249-1256
67. Fajadet J., Morice M.C., Bode C., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111 (2005) 1040-1044
68. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
69. Chu W.W., Rha S.W., Kuchulakanti P.K., et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 97 (2006) 34-37
70. Kahan B.D., and The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 356 (2000) 194-202
71. Hausleiter J., Kastrati A., Mehilli J., et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-Stent Stenosis (OSIRIS) Trial. Circulation 110 (2004) 790-795
72. Waksman R., Ajani A.E., Pichard A.D., et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 44 (2004) 1386-1392
73. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
74. Mann M.J., Gibbons G.H., Tsao P.S., et al. Cell cycle inhibitin preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 99 (1997) 1295-1301
75. Mann M.J., Whittemore A.D., Donaldson M.C., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354 (1999) 1493-1498
76. Alexander J.H., Hafley G., Harrington R.A., et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294 (2005) 2446-2454
77. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
78. Werner N., Junk S., Laufs U., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 93 (2003) e17-e24
79. Shi Y., O'Brien J.E., Fard A., Mannion J.D., Wang D., and Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94 (1996) 1655-1664
80. Han C.I., Campbell G.R., and Campbell J.H. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 38 (2001) 113-119
81. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
82. Rotmans J.I., Heyligers J.M., Verhagen H.J., et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 112 (2005) 12-18
83. Kong D., Melo L.G., Mangi A.A., et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 109 (2004) 1769-1775